BACKGROUND: Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and its complications. Viral eradication is essential to prevent disease progression and reduces liver-related mortality and morbidity. Since the availability of direct-acting antivirals (DAA), HCV treatment has changed significantly. Current treatment strategies for different groups of patients as well as potential risks and caveats will be discussed in this review. SUMMARY: Interferon-free (IFN-free) treatment not only shortens treatment duration, but also achieves high rates of viral clearance and is overall well tolerated. Genotype-restricted but also pangenotypic combinations are available. Usually two DAA of different drug classes are combined. For the majority of the patients, treatment duration ranges from 8 to 12 weeks. Liver and kidney function as well as prior treatment experience and potential drug-drug interactions influence substance choices and treatment duration. However, modern IFN-free treatment is not only safer, but also overall far more simplified and effective. Global HCV eradication might be an ambitious but not completely unrealistic goal to pursue. KEY MESSAGES: IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life.
BACKGROUND: Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and its complications. Viral eradication is essential to prevent disease progression and reduces liver-related mortality and morbidity. Since the availability of direct-acting antivirals (DAA), HCV treatment has changed significantly. Current treatment strategies for different groups of patients as well as potential risks and caveats will be discussed in this review. SUMMARY: Interferon-free (IFN-free) treatment not only shortens treatment duration, but also achieves high rates of viral clearance and is overall well tolerated. Genotype-restricted but also pangenotypic combinations are available. Usually two DAA of different drug classes are combined. For the majority of the patients, treatment duration ranges from 8 to 12 weeks. Liver and kidney function as well as prior treatment experience and potential drug-drug interactions influence substance choices and treatment duration. However, modern IFN-free treatment is not only safer, but also overall far more simplified and effective. Global HCV eradication might be an ambitious but not completely unrealistic goal to pursue. KEY MESSAGES: IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life.
Entities:
Keywords:
Antiviral therapy; Complications; Hepatitis C virus; Side effects; Treatment
Authors: Varun Saxena; Farrukh M Koraishy; Meghan E Sise; Joseph K Lim; Monica Schmidt; Raymond T Chung; Annmarie Liapakis; David R Nelson; Michael W Fried; Norah A Terrault Journal: Liver Int Date: 2016-03-24 Impact factor: 5.828
Authors: María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix Journal: J Hepatol Date: 2016-04-13 Impact factor: 25.083
Authors: Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal Journal: Gastroenterology Date: 2015-05-15 Impact factor: 22.682
Authors: Edward Gane; Eric Lawitz; David Pugatch; Georgios Papatheodoridis; Norbert Bräu; Ashley Brown; Stanislas Pol; Vincent Leroy; Marcello Persico; Christophe Moreno; Massimo Colombo; Eric M Yoshida; David R Nelson; Christine Collins; Yang Lei; Matthew Kosloski; Federico J Mensa Journal: N Engl J Med Date: 2017-10-12 Impact factor: 91.245
Authors: Marc Bourlière; Stuart C Gordon; Steven L Flamm; Curtis L Cooper; Alnoor Ramji; Myron Tong; Natarajan Ravendhran; John M Vierling; Tram T Tran; Stephen Pianko; Meena B Bansal; Victor de Lédinghen; Robert H Hyland; Luisa M Stamm; Hadas Dvory-Sobol; Evguenia Svarovskaia; Jie Zhang; K C Huang; G Mani Subramanian; Diana M Brainard; John G McHutchison; Elizabeth C Verna; Peter Buggisch; Charles S Landis; Ziad H Younes; Michael P Curry; Simone I Strasser; Eugene R Schiff; K Rajender Reddy; Michael P Manns; Kris V Kowdley; Stefan Zeuzem Journal: N Engl J Med Date: 2017-06-01 Impact factor: 91.245
Authors: Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal; Graham R Foster; William L Irving Journal: J Hepatol Date: 2016-07-05 Impact factor: 30.083
Authors: Zelalem A Mekonnen; Makutiro G Masavuli; Wenbo Yu; Jason Gummow; Dawn M Whelan; Zahraa Al-Delfi; Joseph Torresi; Eric J Gowans; Branka Grubor-Bauk Journal: Front Microbiol Date: 2020-11-24 Impact factor: 5.640
Authors: Matthew A Burchill; Matthew P Salomon; Lucy Golden-Mason; Amanda Wieland; Ana C Maretti-Mira; Michael Gale; Hugo R Rosen Journal: PLoS Pathog Date: 2021-08-09 Impact factor: 7.464